Since the takeover of Spanish company Gema SA and its wholly-owned subsidiary Biochemie GmbH by Switzerland's Sandoz, its production facility in Les Franqueses has been continuously upgraded and expanded, and is now the main production unit for semi-synthetic penicillins within the Biochemie group. It is one of the largest manufacturing sites in the world for amino- and isoxazole penicillins, according to the company.
Now, to further improve the organization of the group and create a homogeneous branding of products in world markets, Gema has been renamed Biochemie SA. The group has three state of-the-art plants for making beta lactam, penicillin and cephalosporin located in Austria, Spain and Indonesia.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze